Overview

A Study to Assess the Long-term Safety and Tolerability of TMC114/Rtv in HIV-1 Infected Participants After Rolling-over From Other TMC114 Trials

Status:
Completed

Trial end date:
2009-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study was primarily to assess the long-term safety and tolerability of TMC114/rtv in addition to an individually optimized background antiretroviral therapy in HIV-1 infected participants. In addition, antiviral activity and immunological effect were also evaluated.

Phase:

Phase 2

Details

Lead Sponsor:

Tibotec Pharmaceuticals, Ireland

Treatments:

Darunavir
Ritonavir